相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lipophilicity and hydrophobicity considerations in bio-enabling oral formulations approaches - a PEARRL review
Felix Ditzinger et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2019)
A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation
Sean C. Murphy et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents
Michael W. Jann et al.
CNS DRUGS (2018)
The antimalarial pipeline
Rob Hooft van Huijsduijnen et al.
CURRENT OPINION IN PHARMACOLOGY (2018)
Drug resistance in Plasmodium
Kasturi Haldar et al.
NATURE REVIEWS MICROBIOLOGY (2018)
Mechanisms of resistance to the partner drugs of artemisinin in the malaria parasite
Rowena E. Martin et al.
CURRENT OPINION IN PHARMACOLOGY (2018)
Plasmodium falciparum In Vitro Culture - The Highs and Lows
Sandra Duffy et al.
TRENDS IN PARASITOLOGY (2018)
Assessing drug efficacy against Plasmodium falciparum liver stages in vivo
Erika L. Flannery et al.
JCI INSIGHT (2018)
High-concentration protein formulations: How high is high?
Patrick Garidel et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2017)
Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies
Gianna Triller et al.
IMMUNITY (2017)
Progress with the PfSPZ Vaccine for malaria
Brian Greenwood
LANCET INFECTIOUS DISEASES (2017)
Does antimalarial mass drug administration increase or decrease the risk of resistance?
Nicholas J. White
LANCET INFECTIOUS DISEASES (2017)
DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection
Mihly Sulyok et al.
LANCET INFECTIOUS DISEASES (2017)
Measuring the impact of seasonal malaria chemoprevention as part of routine malaria control in Kita, Mali
Fatou Diawara et al.
MALARIA JOURNAL (2017)
New developments in anti-malarial target candidate and product profiles
Jeremy N. Burrows et al.
MALARIA JOURNAL (2017)
Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase
Tanya Paquet et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Towards a Humanized Mouse Model of Liver Stage Malaria Using Ectopic Artificial Livers
Shengyong Ng et al.
SCIENTIFIC REPORTS (2017)
malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication
David C. Kaslow et al.
PLOS MEDICINE (2017)
malERA: An updated research agenda for malaria elimination and eradication
Regina N. Rabinovich et al.
PLOS MEDICINE (2017)
Malaria
Margaret A. Phillips et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans
Christoph D. Spinner et al.
INFECTION (2016)
Cost evaluation of antibody production processes in different operation modes
Stephan Klutz et al.
CHEMICAL ENGINEERING SCIENCE (2016)
Effectiveness of twice a week prophylaxis with atovaquone-proguanil (Malarone®) in long-term travellers to West Africa
Tamar Lachish et al.
JOURNAL OF TRAVEL MEDICINE (2016)
Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria
Nicholas J. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Parasites resistant to the antimalarial atovaquone fail to transmit by mosquitoes
Christopher D. Goodman et al.
SCIENCE (2016)
Effects of Response to 2014-2015 Ebola Outbreak on Deaths from Malaria, HIV/AIDS, and Tuberculosis, West Africa
Alyssa S. Parpia et al.
EMERGING INFECTIOUS DISEASES (2016)
Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies
Diego A. Espinosa et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Malaria kills more than Ebola virus disease
Franco Pagnoni et al.
LANCET INFECTIOUS DISEASES (2015)
Effect of the Ebola-virus-disease epidemic on malaria case management in Guinea, 2014: a cross-sectional survey of health facilities
Mateusz M. Plucinski et al.
LANCET INFECTIOUS DISEASES (2015)
Malaria morbidity and mortality in Ebola-affected countries caused by decreased health-care capacity, and the potential effect of mitigation strategies: a modelling analysis
Patrick G. T. Walker et al.
LANCET INFECTIOUS DISEASES (2015)
A novel multiple-stage antimalarial agent that inhibits protein synthesis
Beatriz Baragana et al.
NATURE (2015)
Hit and lead criteria in drug discovery for infectious diseases of the developing world
Kei Katsuno et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Malaria medicines: a glass half full?
Timothy N. C. Wells et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model
Jie Zhao et al.
PHARMACEUTICAL RESEARCH (2015)
Long-acting antiviral agents for HIV treatment
David A. Margolis et al.
CURRENT OPINION IN HIV AND AIDS (2015)
Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes
Jan Lycke
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission
Kelli L. Kuhen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Of men in mice: the success and promise of humanized mouse models for human malaria parasite infections
Alexis Kaushansky et al.
CELLULAR MICROBIOLOGY (2014)
Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection
Lander Foquet et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Screening and hit evaluation of a chemical library against blood-stage Plasmodium falciparum
Vicky M. Avery et al.
MALARIA JOURNAL (2014)
Clinical development success rates for investigational drugs
Michael Hay et al.
NATURE BIOTECHNOLOGY (2014)
Asymptomatic malaria infections: detectability, transmissibility and public health relevance
Teun Bousema et al.
NATURE REVIEWS MICROBIOLOGY (2014)
Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites
Selidji Todagbe Agnandji et al.
PLOS MEDICINE (2014)
The history of monoclonal antibody development - Progress, remaining challenges and future innovations
Justin K. H. Liu
ANNALS OF MEDICINE AND SURGERY (2014)
Factors Influencing Magnitude and Duration of Target Inhibition Following Antibody Therapy: Implications in Drug Discovery and Development
Anjaneya P. Chimalakonda et al.
AAPS JOURNAL (2013)
Are monoclonal antibodies a safe treatment for cancer during pregnancy?
Maria Anna Sarno et al.
IMMUNOTHERAPY (2013)
The Open Access Malaria Box: A Drug Discovery Catalyst for Neglected Diseases
Thomas Spangenberg et al.
PLOS ONE (2013)
Long-acting injectable antiretrovirals for HIV treatment and prevention
William R. Spreen et al.
CURRENT OPINION IN HIV AND AIDS (2013)
Drug Screen Targeted at Plasmodium Liver Stages Identifies a Potent Multistage Antimalarial Drug
Filipa P. da Cruz et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Effectiveness of Long-Acting Reversible Contraception
Brooke Winner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Yaws Eradication: Facing Old Problems, Raising New Hopes
Andrea Rinaldi
PLOS NEGLECTED TROPICAL DISEASES (2012)
Doxycycline for Malaria Chemoprophylaxis and Treatment: Report from the CDC Expert Meeting on Malaria Chemoprophylaxis
Kathrine R. Tan et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2011)
Strategies for extended serum half-life of protein therapeutics
Roland E. Kontermann
CURRENT OPINION IN BIOTECHNOLOGY (2011)
Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery
Stephan Meister et al.
SCIENCE (2011)
Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge
Hatem A. Azim et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2010)
Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets
Jasmine P. Davda et al.
MABS (2010)
Thousands of chemical starting points for antimalarial lead identification
Francisco-Javier Gamo et al.
NATURE (2010)
Chemical genetics of Plasmodium falciparum
W. Armand Guiguemde et al.
NATURE (2010)
Strategies to Extend Plasma Half-Lives of Recombinant Antibodies
Roland E. Kontermann
BIODRUGS (2009)
An Interspecies Comparison of Placental Antibody Transfer: New Insights Into Developmental Toxicity Testing of Monoclonal Antibodies
Nele Pentsuk et al.
BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY (2009)
Acquired Immunity to Malaria
Denise L. Doolan et al.
CLINICAL MICROBIOLOGY REVIEWS (2009)
Industrialization of mAb production technology The bioprocessing industry at a crossroads
Brian Kelley
MABS (2009)
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen
David Plouffe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A systematic review and meta-analysis of the effectiveness and safety of atovaquone-proguanil (Malarone) for chemoprophylaxis against malaria
Halima Nakato et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Solubilizing excipients in oral and injectable formulations
RG Strickley
PHARMACEUTICAL RESEARCH (2004)
Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: Results of an international, randomized, open-label study
D Camus et al.
CLINICAL INFECTIOUS DISEASES (2004)
Atovaquone-proguanil for prophylaxis and treatment of malaria
F Marra et al.
ANNALS OF PHARMACOTHERAPY (2003)
Atovaquone/Proguanil - A review of its use for the prophylaxis of Plasmodium falciparum malaria
K McKeage et al.
DRUGS (2003)
Randomized, placebo-controlled trial of Atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia
J Ling et al.
CLINICAL INFECTIOUS DISEASES (2002)
Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: Results from a randomized, double-blind study
D Overbosch et al.
CLINICAL INFECTIOUS DISEASES (2001)
Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers:: a randomised, double-blind study
B Hogh et al.
LANCET (2000)
分享论文
